Thanks. Generally, I think the health and biotech sector is one of the few sectors where there is considerable value in our market and has been pretty unloved over the last few years. This is compounded by momentum/investment bank trading (and shorting) which has amplfiied the disconnect between price and value (in my opinion) with the added bonus of EoFY tax loss selling for individual investors. PNV seems to tick the boxes for growth and having a solid underlying business (although not quite the same cash pile as Neuren has).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
-0.030(2.49%) |
Mkt cap ! $811.7M | |||
| Open | High | Low | Value | Volume |
| $1.21 | $1.25 | $1.17 | $2.698M | 2.265M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4273 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 10804 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| PNV (ASX) Chart |